Responses
Clinical and epidemiological research
Extended report
Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial
Compose a Response to This Article
Other responses
No responses have been published for this article.